Sargent Rachel E, Barrio Andrea V, Sevilimedu Srinivasa V, Khan Atif J, Morrow Monica, Mamtani Anita
Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ann Surg Oncol. 2025 Jul 16. doi: 10.1245/s10434-025-17784-x.
Randomized trials established the safety of postmastectomy radiation/regional nodal irradiation (PMRT) as an alternative to axillary lymph node dissection (ALND) for cN0 patients undergoing upfront mastectomy with one or two positive sentinel lymph nodes (+SLNs). In January 2022, the authors adopted a policy omitting routine frozen section for cT1-3N0 patients undergoing upfront mastectomy, and this study sought to examine the impact of this policy on axillary treatment.
Consecutive patients with cT1-3N0 breast cancer who underwent upfront mastectomy from January 2022 to July 2023 were identified. For patients with three or more +SLNs and those with one or two +SLNs not meeting institutional PMRT criteria, ALND was indicated. This study evaluated ALND/PMRT rates after adoption of this policy.
In this study, 623 patients with cT1-3N0 breast cancer had upfront mastectomy with sentinel lymph node biopsy. Overall, 4.7% (n = 29) of the patients had completion ALND (cALND). These patients had larger tumors, and more often had lobular histology and LVI. Of 98 patients with one or two +SLNs, 86 (88%) underwent PMRT and no further surgery, and 8 (8%) had ALND due to no initial PMRT indication, of whom 2 then met PMRT criteria based on additional positive nodes, and 4 had neither. Among those with three or more +SLNs (n = 29), 21 (72%) underwent both ALND and PMRT, and 8 (28%) had PMRT alone or neither treatment. Overall, return to the operating room for ALND was indicated for 39 (6.2%) of the 623 patients with three or more +SLNs and for those who had one or two +SLNs without PMRT indication.
In this study, only 6% of the cN0 patients who had SLN frozen section omitted at upfront mastectomy exhibited an indication for cALND. Receipt of ALND+PMRT for the patients with involvement of one or two nodes was rare, occurring for just 2% of the patients. Axillary management was optimized by routine omission of frozen section for cT1-3N0 patients undergoing upfront mastectomy.
随机试验证实,对于接受一期乳房切除术且前哨淋巴结(SLN)有一或两个阳性的cN0患者,乳房切除术后放疗/区域淋巴结照射(PMRT)作为腋窝淋巴结清扫术(ALND)的替代方案是安全的。2022年1月,作者采用了一项政策,即对接受一期乳房切除术的cT1-3N0患者省略常规冰冻切片检查,本研究旨在探讨该政策对腋窝治疗的影响。
确定2022年1月至2023年7月期间接受一期乳房切除术的连续cT1-3N0乳腺癌患者。对于前哨淋巴结有三个或更多阳性的患者以及前哨淋巴结有一或两个阳性但不符合机构PMRT标准的患者,建议进行ALND。本研究评估了采用该政策后的ALND/PMRT率。
在本研究中,623例cT1-3N0乳腺癌患者接受了一期乳房切除术及前哨淋巴结活检。总体而言,4.7%(n = 29)的患者接受了完整腋窝淋巴结清扫术(cALND)。这些患者的肿瘤较大,更常为小叶组织学类型且有淋巴管浸润(LVI)。在98例前哨淋巴结有一或两个阳性的患者中,86例(88%)接受了PMRT且未进行进一步手术,8例(8%)因最初无PMRT指征而接受了ALND,其中2例因额外的阳性淋巴结后来符合PMRT标准,4例两者均不符合。在前哨淋巴结有三个或更多阳性的患者中(n = 29),21例(72%)接受了ALND和PMRT,8例(28%)仅接受了PMRT或未接受任何治疗。总体而言,623例前哨淋巴结有三个或更多阳性的患者以及前哨淋巴结有一或两个阳性且无PMRT指征的患者中,有39例(6.2%)需要返回手术室进行ALND。
在本研究中,一期乳房切除术时省略前哨淋巴结冰冻切片检查的cN0患者中,仅6%有cALND指征。对于前哨淋巴结有一或两个阳性的患者,接受ALND + PMRT的情况很少见,仅占患者的2%。对于接受一期乳房切除术的cT1-3N0患者,通过常规省略冰冻切片检查优化了腋窝管理。